Fil LTD Apellis Pharmaceuticals, Inc. Transaction History

Fil LTD

$103 Billion
Q3 2024

A detailed history of Fil LTD transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Fil LTD holds 11,467 shares of APLS stock, worth $337,015. This represents 0.0% of its overall portfolio holdings.

Number of Shares

11,467

Previous 11,087 3.43%

Holding current value

$337,015

Previous $425,000 22.35%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$28.84 - $41.15 $10,959 - $15,637	380 Added 3.43%	11,467 $330,000
Q2 2024 Aug 13, 2024	BUY	$38.07 - $59.71 $189,550 - $297,296	4,979 Added 81.52%	11,087 $425,000
Q1 2024 May 13, 2024	BUY	$55.39 - $72.47 $23,873 - $31,234	431 Added 7.59%	6,108 $359,000
Q4 2023 Feb 13, 2024	BUY	$37.14 - $64.82 $210,843 - $367,983	5,677 New	5,677 $339,000
Q3 2021 Nov 15, 2021	SELL	$31.4 - $69.84 $9.7 Million - $21.6 Million	-309,031 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$40.9 - $64.9 $59,550 - $94,494	1,456 Added 0.47%	309,031 $19.5 Million
Q1 2021 May 14, 2021	SELL	$40.8 - $57.39 $472,423 - $664,518	-11,579 Reduced 3.63%	307,575 $13.2 Million
Q4 2020 Feb 08, 2021	BUY	$30.79 - $57.2 $5.85 Million - $10.9 Million	189,835 Added 146.8%	319,154 $18.3 Million
Q3 2020 Nov 13, 2020	SELL	$25.89 - $33.65 $22 Million - $28.6 Million	-850,397 Reduced 86.8%	129,319 $3.9 Million
Q2 2020 Aug 13, 2020	SELL	$24.8 - $38.49 $3.09 Million - $4.8 Million	-124,633 Reduced 11.29%	979,716 $32 Million
Q1 2020 May 14, 2020	SELL	$17.91 - $44.33 $5.19 Million - $12.9 Million	-289,936 Reduced 20.79%	1,104,349 $29.6 Million
Q4 2019 Feb 07, 2020	BUY	$22.1 - $30.8 $6.57 Million - $9.15 Million	297,083 Added 27.08%	1,394,285 $42.7 Million
Q3 2019 Nov 13, 2019	BUY	$24.09 - $32.18 $26.4 Million - $35.3 Million	1,097,202 New	1,097,202 $26.4 Million

Others Institutions Holding APLS

# of Institutions

303

Shares Held

112M

Call Options Held

3.85M

Put Options Held

1.09M

View Full List

About Apellis Pharmaceuticals, Inc.

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $3.23B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

More about APLS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fil LTD, based on Form 13F filings with the SEC.

News

Stay updated on Fil LTD with notifications on news.

Account